MyFinsight
Home
Blog
About
Proceeds from issuance of
warrants and pre-funded...
$27,548K
(52.65%↑ Y/Y)
Proceeds from exercise of
warrants and pre-funded...
$1,654K
Proceeds from exercise of
stock options
$815K
Net cash provided by
financing activities
$30,017K
(78.69%↑ Y/Y)
Net (decrease)
increase in cash, cash...
$1,013K
(-79.88%↓ Y/Y)
Canceled cashflow
$29,004K
Loss on issuance of
liability-classified warrants
-$87,559K
Stock-based compensation
$23,838K
(816.49%↑ Y/Y)
Issuance of ascendant
liability-classified pre-funded...
$20,119K
Accrued expenses
$15,836K
(1239.28%↑ Y/Y)
Deposits
$1,047K
(128.60%↑ Y/Y)
Accounts payable
$421K
(-47.64%↓ Y/Y)
Decrease in the carrying
amount of...
$372K
(-74.83%↓ Y/Y)
Depreciation and
amortization
$36K
(-82.00%↓ Y/Y)
Net cash used in
operating activities
-$29,004K
(-150.32%↓ Y/Y)
Canceled cashflow
$149,228K
Net loss
-$153,067K
(-638.06%↓ Y/Y)
Changes in fair value of
financial instruments
$24,487K
Operating lease liability
-$376K
(75.74%↑ Y/Y)
Prepaid expenses and
other current assets
$233K
(-84.92%↓ Y/Y)
Other payable
-$43K
(-122.75%↓ Y/Y)
Accounts receivable
$26K
(106.30%↑ Y/Y)
Back
Back
Cash Flow
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)
source: myfinsight.com